A Phase 4 interventional study of Eptinezumab in Migraine, sponsored by H. Lundbeck A/S. Completed at 21 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by H. Lundbeck A/S · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing eptinezumab in Migraine Disorders — 6 open to participants now, 6 under way, 5 of them phase 3. eptinezumab · Migraine Disorders.
Among the 21 studies testing eptinezumab in Migraine Disorders, this one is the 12th largest by enrollment, is the only one that started in 2024, is one of 4 in phase 4, and was the 19th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →6 of the 21 studies testing eptinezumab in Migraine Disorders are open now, in 11 countries. Recruiting first, the newest first:
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18–65
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 6–17
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 6–17
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 12–17
Dr George Medvedev · Sites in Canada
Ages 19–75
By country, each count listing its studies:
eptinezumab: first FDA approval 2020 (VYEPTI), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 164 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 193 across the 21 interventional studies. Of the 15 that completed or were terminated, 8 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 21 have an industry lead sponsor. The 5 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
23 studies in Migraine Disorders by H. Lundbeck A/S: 3 open now, 3 under way, 3 of them phase 3. Of 20 finished, 9 (45%) have results posted.
Among the 23 studies in Migraine Disorders by H. Lundbeck A/S, this one is the 14th largest by enrollment, is one of 3 that started in 2024, is one of 3 in phase 4, and was the 23rd registered.
H. Lundbeck A/S’s Migraine Disorders studies by the year they started, since 2012.
3 of the studies testing eptinezumab in Migraine Disorders that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04965675Phase 3H. Lundbeck A/SA Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine | 2027-03-26 |
| NCT07191145Phase 3Sunnybrook Health Sciences CentreEary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT) | 2027-06-30 |
| NCT05897320Phase 3H. Lundbeck A/SA Study of Eptinezumab in Pediatric Participants With Episodic Migraine | 2027-07-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies testing eptinezumab in Migraine Disorders, from their registry updates:
Among H. Lundbeck A/S’s 23 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
The main goal of this trial is to learn whether eptinezumab improves migraine symptoms and quality of life of participants with migraine who did not perceive a sufficient improvement during previous treatment with therapies targeting calcitonin gene-related peptide (CGRP).
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol-defined inclusion and exclusion criteria apply.
Participants will receive eptinezumab at Baseline (Day 1) and Week 12
Drug: Eptinezumab
Solution for infusion
Number of Participants with Response of "Much Improved" or "Very Much Improved" on the Patient Global Impression of Change (PGIC) Scale
Time frame: Week 24
Change from Baseline in Monthly Migraine Days (MMDs)
Time frame: Weeks 1-12 and 13-24
Change from Baseline in the Percentage of MMDs with Severe Pain Intensity
Time frame: Weeks 1-12 and 13-24
Change from Baseline in Monthly Headache Days (MHDs)
Time frame: Weeks 1-12 and 13-24
Change from Baseline in MMDs with Use of Acute Medication
Time frame: Weeks 1-12 and 13-24
Number of Participants with Response of "Much Improved" or "Very Much Improved" on the PGIC Scale
Time frame: Week 12
PGIC Score
Time frame: Weeks 12 and 24
Change from Baseline in Migraine Disability Assessment (MIDAS) Scores
Time frame: Weeks 12 and 24
Goal Attainment Scaling (GAS) Score
Time frame: Weeks 12 and 24
Number of Participants with GAS Score ≥50
Time frame: Weeks 12 and 24
Change from Baseline in Number of Good Days per Month
Time frame: Weeks 12 and 24
Change from Baseline in Migraine Clinical Outcome Assessment System-Cognition (MiCOAS-COG) Score
Time frame: Weeks 12 and 24
Number of Participants with Response of "Much Improved" or "Very Much Improved" in Brain Fog
Time frame: Weeks 12 and 24
Brain Fog Score
Time frame: Weeks 12 and 24
Number of Participants with Response of "Much Improved" or "Very Much Improved" on the Clinical Global Impression of Change (CGIC) Scale
Time frame: Weeks 12 and 24
CGIC Score
Time frame: Weeks 12 and 24
Number of Participants with Adverse Events (AEs)
Time frame: Up to Week 26
Ran from Dec 2024 to primary completion in Sep 2026, 20 months.
Of 28 industry-sponsored phase 4 interventional studies under Migraine Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's 20 months is below that.
Counting every sponsor, half of 77 studies reached it within 27 months; a quarter within 17 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eptinezumab